ClinicalTrials.gg
TerminatedNCT06321562Updated Jul 16, 2025

Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma

A Phase 1 interventional study of TimoD implant and Injector system in Primary Open-angle Glaucoma, sponsored by EyeD Pharma. Terminated at 5 sites in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by EyeD Pharma · Phase 1, Interventional, and Other

Why this study was terminated
The study was terminated early due to the difficulties to enrol participant

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2023, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Glaucoma, Open-Angle with a site in Germany — 7 open to participants now, 11 under way, none of them phase 3. Glaucoma, Open-Angle · Germany.

Enrollment
46th of 46
1 · median 60
Started
2023
with 4 others
Phase 1
2 of 64
none open now
Registered
61st of 64
by date

Among the 64 studies in Glaucoma, Open-Angle with a site in Germany, this one is the 46th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2023, is one of 2 in phase 1, and was the 61st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

7 of the 64 studies in Glaucoma, Open-Angle with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Glaucoma, Open-Angle with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma and pseudophakia (currently present or to be performed during the concomitant implantation surgery in subjects with age-related cataract eligible to intra-capsular IOL placement). The main questions it aims to answer are how safe the investigational drug is and how the body tolerates it.

The study will also check:

  • how safely the implant is placed in and removed from the eye and how the body responds to the procedure,
  • how safe different doses of timolol are and how the body handles taking it,
  • the amount of Timolol released in the bloodstream,
  • if there is any positive effect on the pressure inside the eye.
Read the detailed description

Timolol will be delivered through an investigational drug called 'TimoD implant'. This implant is placed inside one eye, the study eye, with the help of an instrument (investigational device) called an injector system.

Three dose ranges of TimoD implant will be tested (low, intermediate, and high) in 3 groups of 6 participants.

The Timolol will be released slowly through the implant for up to 1 year (main phase).

Approximately 1 year after the TimoD implant is placed into the eye and in absence of contraindications, the participants will be invited to continue the study in an extension phase. If the participants agree to enter the extension phase and the study investigator confirms it is safe for them, the TimoD implant will remain in the study eye for one additional year.

03

Conditions studied

  • Primary Open-angle Glaucoma

Keywords

  • Glaucoma
  • POAG
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • In good general and mental health without ongoing abnormalities in medical history.
  • Clinically proven diagnosis of primary open-angle glaucoma (POAG) in the previous 12 months.
  • Subjects with IOP not adequately controlled with the standard medication.
  • Pseudophakia.

Exclusion criteria

Exclusion Criteria:

  • Concomitant treatment with timolol (systemic), , cytochrome P450 2D6 inhibitors, or α2-agonists.
  • Subjects with a history of or to β-blockers.
  • Significant risks caused by washout of ocular hypotensive medications.
  • History of any glaucoma not specified as POAG.
  • History of elevated IOP due to corticosteroid use.
  • History of ocular trauma.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Group 1: TimoD implant-Dose 1 (low dose)

    Participants in the Group 1 will receive a low dose of TimoD implant in the study eye on Day 1.

    Drug: TimoD implant · Device: Injector system

  • Experimental
    Group 2: TimoD implant-Dose 2 (intermediate dose)

    Participants in Group 2 will receive an intermediate dose of TimoD implant in the study eye on Day 1 if all participants in Group 1 have completed a 4-week treatment period with the lowest dose of TimoD implant, providing there are no safety issues in Group 1.

    Drug: TimoD implant · Device: Injector system

  • Experimental
    Group3: TimoD implant-Dose 3 (high dose)

    Participants in Group 3 will receive a high dose of TimoD implant in the study eye on Day 1 if all participants in Group 2 have completed a 4-week treatment period with the intermediate dose, providing there are no safety issues in Group 2.

    Drug: TimoD implant · Device: Injector system

Interventions

  • Consists of 1 TimoD implant administration in the study eye

    Also known as: Intraocular implant releasing timolol, Investigational drug

  • DeviceInjector system

    This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as an"intraocular implant injection system" outside of its scope of intended use.

    Also known as: ACCUJECT™ 2.2.-BL, Investigational device

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants experiencing one or more serious adverse events (SAEs)

    Time frame: From screening visit (up to Day -41) to end of study (Week 108)

  2. Number and proportion of participants experiencing one or more treatment-emergent adverse events (TEAEs) overall and by dose group

    Time frame: From screening visit (up to Day -41) to end of study (Week 108)

07

Study locations

5 sites
  • Breyer, Kaymak & Klabe Augenchirurgie
    Düsseldorf, 40212, Germany
  • Universitäts-Augenklinik Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsaugenklinik Magdeburg
    Magdeburg, 39120, Germany
  • Augenklinik Sulzbach
    Sulzbach, 66280, Germany
  • Universitäts-Augenklinik Tübingen
    Tübingen, 72076, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jun 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 20, 2024
StartActual
Mar 1, 2023
Primary completionActual
Jun 26, 2025
CompletionActual
Jun 26, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06321562
Lead sponsor
EyeD Pharma
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Mar 1, 2023
Primary completion
Jun 26, 2025
Completion
Jun 26, 2025
Last update
Jul 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drugs, Investigational

Start the discussion